Worldwide Influenza Vaccines Market Valuation to Surpass USD 7.5 Billion By 2027

February 22, 2021


According to the research report titled ‘Worldwide Influenza Vaccines Market Size, Share, Analysis, Growth, Trends, and Forecast to 2027’, available with Market Study Report LLC, global Influenza vaccines market valuation is expected to exceed USD 7.5 billion by the year 2027.
 

The research delves into exigencies that will drive the global influenza vaccines market growth while also shedding light on the plethora of challenges that will be braved by the industry players through the forecast period.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2543898/
 

Embellished with over 23 tables and 100 statistics, this report consists of a qualitative analysis of the worldwide influenza vaccines market size, in terms of both volume and value. It also provides updated information on the current market scenario and stipulates a growth trajectory for the industry through 2027, while taking into consideration the performance history during 2013-2019. 
 

Furthermore, an extensive analysis of industry segmentation, in consort with details market share holding and year-on-year growth (%) of each segment are also provided.
 

The research report elucidates the latest data on number of adults and children vaccinated for influenza across the world. It also provides valuable insights into the highest-ranking 21 national and regional markets in terms of revenue generated via influenza vaccines, and make relevant forecasts till 2027.
 

Moreover, the report includes complete ins and outs of game-changing industry developments like exclusive agreements, licensing, mergers and acquisitions, distribution partnerships, and collaboration deals among market moguls. Crucial details about vaccine study phases, recruitment for clinical trials, sponsor names, and trial status during the period 2019-2020 are elaborated. Particulars about the regulations landscape, in addition to vaccine approval procedures, and an outline of the regulatory bodies in the US, Japan, and EU are also included.
 

Comprehensive profiling of major industry players, alongside specifics about promising vaccines in clinical developments, sales volume analysis, business overview, and details of vaccines portfolio are illustrated.
 

Key contenders in the worldwide influenza vaccine market are Altimmune, Inc., Sanofi S.A, BioDiem, GlaxoSmithKline plc, Medicago, Inc., Pneumagen Ltd., Seqirus, Shanghai Institute of Biological Products Co. Ltd., AstraZeneca plc, Gamma Vaccines Pty Ltd., Hualan Biological Engineering, Inc., Mylan N.V., Novavax, Inc., BiondVax Pharmaceuticals Ltd., Moderna, Inc., Daiichi Sankyo Company, Limited, FluGen, Inc., and Imutex Limited.

 

Chat with us